{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 447439143
| IUPAC_name = 6-[2-[4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl]ethyl]-7-methyl-[1,3]thiazolo[2,3-b]pyrimidin-5-one
| image = Ritanserin2DCSD.svg

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 87051-43-2
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 5074
| IUPHAR_ligand = 97
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 145TFV465S
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 267777
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 64195
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 4896

<!--Chemical data-->
| molecular_weight = 477.569 g/mol
| smiles = CC1=C(C(=O)N2C=CSC2=N1)CCN3CCC(=C(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F)CC3
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C27H25F2N3OS/c1-18-24(26(33)32-16-17-34-27(32)30-18)12-15-31-13-10-21(11-14-31)25(19-2-6-22(28)7-3-19)20-4-8-23(29)9-5-20/h2-9,16-17H,10-15H2,1H3
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey       = JUQLTPCYUFPYKE-UHFFFAOYSA-N
}}

'''Ritanserin''' ([[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]], [[British Approved Name|BAN]]) is a [[serotonin antagonist|serotonin receptor antagonist]] which was never marketed for [[clinical use]] but has been used in [[scientific research]].<ref name="MortonMorton1999">{{cite book|author1=Dr. Ian Morton|author2=I.K. Morton|author3=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=mqaOMOtk61IC&pg=PA249|date=31 October 1999|publisher=Springer Science & Business Media|isbn=978-0-7514-0499-9|pages=249–}}</ref>

==Research==
Ritanserin was tested in clinical trials for [[schizophrenia]]<ref name="pmid18801405"/> and [[migraine]].<ref>{{cite journal|last=Nappi|first=G|author2=Sandrini, G |author3=Granella, F |author4=Ruiz, L |author5=Cerutti, G |author6=Facchinetti, F |author7=Blandini, F |author8= Manzoni, GC |title=A new 5-HT2 antagonist (ritanserin) in the treatment of chronic headache with depression. A double-blind study vs amitriptyline.|journal=Headache|date=June 1990|volume=30|issue=7|pages=439–44|pmid=2119355|doi=10.1111/j.1526-4610.1990.hed3007439.x}}</ref>

==Pharmacology==
Ritanserin acts as a selective [[5-HT2A receptor|5-HT<sub>2A</sub>]] (K<sub>i</sub> = 0.45 nM) and [[5-HT2C receptor|5-HT<sub>2C</sub> receptor]] (K<sub>i</sub> = 0.71 nM) [[receptor antagonist|antagonist]].<ref name="pmid18801405">{{cite journal |vauthors=Akhondzadeh S, Malek-Hosseini M, Ghoreishi A, Raznahan M, Rezazadeh SA |title=Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study |journal=Progress in neuro-psychopharmacology & biological psychiatry |volume= 32|issue= 8|pages= 1879–83|date=September 2008 |pmid=18801405 |doi=10.1016/j.pnpbp.2008.08.020 |url=http://linkinghub.elsevier.com/retrieve/pii/S0278-5846(08)00258-3}}</ref><ref name="pmid2860558">{{cite journal|vauthors=Leysen JE, Gommeren W, Van Gompel P, Wynants J, Janssen PF, Laduron PM | title=Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist. | journal=Mol Pharmacol | year= 1985 | volume= 27 | issue= 6 | pages= 600–11 | pmid=2860558 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2860558  }}</ref> It has relatively low [[affinity (pharmacology)|affinity]] for the [[Histamine H1 receptor|H<sub>1</sub>]], [[D2 receptor|D<sub>2</sub>]], [[alpha-1 adrenergic receptor|α<sub>1</sub>-adrenergic]], and [[alpha-2 adrenergic receptor|α<sub>2</sub>-adrenergic receptor]]s (39-, 77-, 107-, and 166-fold lower relative to 5-HT<sub>2A</sub>, respectively).<ref name="pmid2860558" /> The affinity of ritanserin for the [[5-HT1A receptor|5-HT<sub>1A</sub> receptor]] is less than 1 µM.<ref name="pmid2860558" /> In addition to its affinity for the 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors, ritanserin also binds to and antagonizes the [[5-HT1D receptor|5-HT<sub>1D</sub>]], [[5-HT2B receptor|5-HT<sub>2B</sub>]], [[5-HT5A receptor|5-HT<sub>5A</sub>]], [[5-HT6 receptor|5-HT<sub>6</sub>]], and [[5-HT7 receptor|5-HT<sub>7</sub> receptor]]s.<ref>{{cite book|title=Harmful Non-Indigenous Species in the United States|url=https://books.google.com/books?id=wSnzKXFtuKwC&pg=PA361|date=1 February 1993|publisher=DIANE Publishing|isbn=978-0-7881-0441-1|pages=361–}}</ref>

The [[atypical antipsychotic]] [[risperidone]] was developed from ritanserin.<ref name="Publishers1994">{{cite book|author=Bentham Science Publishers|title=Current Medicinal Chemistry|url=https://books.google.com/books?id=JMd5FWm6GTkC&pg=PA52|date=May 1994|publisher=Bentham Science Publishers|pages=52–}}</ref>

==See also==
* [[Ketanserin]]

==References==
{{Reflist|2}}

{{Serotonergics}}

[[Category:5-HT2A antagonists]]
[[Category:5-HT2C antagonists]]
[[Category:Abandoned drugs]]
[[Category:Lactams]]
[[Category:Fluoroarenes]]
[[Category:Piperidines]]
[[Category:Thiazolopyrimidines]]


{{nervous-system-drug-stub}}